Series B · BiotechSidewinder Therapeutics: Series BDevelops next-generation bispecific ADCs for cancer treatmentPublished Oct 4, 2026By RoundOS Funding deskFunding historyApr 8, 2026Series B · This round$137MSourcesbusinesswire.com↗
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200MPrivate financing · Oct 23, 2026
Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237MSeries E · Oct 23, 2026
Warp SciencesWarp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.$215MSeries A · Oct 22, 2026
SEGNOSSEGNOS develops magnetic-particle materials and diagnostic technologies for blood testing.UndisclosedPre-Series A · Oct 22, 2026